Medical Oncology Department
Alfredo Carrato has not added Biography.
If you are Alfredo Carrato and would like to personalize this page please email our Author Liaison for assistance.
Anti-VEGF therapy: a new approach to colorectal cancer therapy.
Expert review of anticancer therapy Oct, 2006 | Pubmed ID: 17069524
Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Expert review of anticancer therapy Feb, 2008 | Pubmed ID: 18279056
Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico Jul, 2009 | Pubmed ID: 19574202
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib.
Anti-cancer drugs Jan, 2010 | Pubmed ID: 20110785
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Apr, 2013 | Pubmed ID: 23358972
Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico Sep, 2013 | Pubmed ID: 23359181
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
BMC genomics 05, 2015 | Pubmed ID: 25997541
Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
BMC cancer Oct, 2015 | Pubmed ID: 26498594
Erratum to: The UBC-40 Urothelial Bladder Cancer Cell Line Index: a genomic resource for functional studies.
BMC genomics Nov, 2015 | Pubmed ID: 26621286
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Cancer treatment reviews Nov, 2016 | Pubmed ID: 27676174
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico Jun, 2017 | Pubmed ID: 27995549
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
European journal of cancer (Oxford, England : 1990) 08, 2017 | Pubmed ID: 28633089
A Label Free Disposable Device for Rapid Isolation of Rare Tumor Cells from Blood by Ultrasounds.
Micromachines Mar, 2018 | Pubmed ID: 30424062
Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs.
Cancers Mar, 2019 | Pubmed ID: 30862091
Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".
International journal of molecular sciences Apr, 2019 | Pubmed ID: 30999623
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
BMC cancer Jun, 2019 | Pubmed ID: 31159765
Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.
International journal of molecular sciences Oct, 2019 | Pubmed ID: 31597249
A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants.
EBioMedicine Mar, 2020 | Pubmed ID: 32113160
Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
European journal of cancer (Oxford, England : 1990) Nov, 2020 | Pubmed ID: 32977220
Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico Jan, 2022 | Pubmed ID: 34363594
Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments.
European journal of cancer (Oxford, England : 1990) May, 2022 | Pubmed ID: 35316750
Cristina Galindo-Pumariño1,
Alberto Herrera2,
Alberto Muñoz3,
Alfredo Carrato1,
Mercedes Herrera4,
Cristina Peña1
1Medical Oncology Department, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), CIBERONC,
2Department of Medical Oncology, Hospital Universitario Puerta de Hierro de Majadahonda,
3Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas - Universidad Autónoma de Madrid, CIBERONC,
4Department of Oncology & Pathology, Karolinska Institutet
Jesús Frutos Díaz-Alejo*,1,2,3,4,
Simon April-Monn*,5,
Marina Cihova6,
Verona Buocikova6,
Jorge Villalón López1,3,
Maria Urbanova6,
Carmen G. Lechuga7,
Miroslav Tomas6,8,
Peter Dubovan6,8,
Bárbara Luna Sánchez3,
Sonia Camaño Páez3,
Alfonso Sanjuanbenito2,9,
Eduardo Lobo9,
Estefanía Romio de la Heras10,
Carmen Guerra2,7,
Carolina de la Pinta11,
Emma Barreto Melian1,2,
Mercedes Rodríguez Garrote1,2,
Alfredo Carrato1,2,4,
Laura Ruiz-Cañas3,12,13,
Bruno Sainz, Jr.2,3,12,13,
Ana Torres3,
Bozena Smolkova6,
Julie Earl1,2,3
1Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS),
2, The Biomedical Research Network in Cancer (CIBERONC),
3Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS),
4Faculty of Medicine, University of Alcalá de Henares,
5Institute of Tissue Medicine and Pathology, University of Bern,
6Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences,
7Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO),
8Department of Surgical Oncology, National Cancer Institute, Slovak Medical University,
9Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal,
10Department of Pathology, Hospital Universitario Ramón y Cajal,
11Department of Radiation Oncology, Hospital Universitario Ramón y Cajal,
12Department of Cancer, Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM),
13Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados